MyBioSource

antibody

BRCA1 Monoclonal Antibody

MBS190077

0.1 mg

420 USD

monoclonal

mouse

human

western blot, immunoprecipitation

MBS190077

Antibody

BRCA1 Monoclonal Antibody

BRCA1

Anti-BRCA1; BRCA1

BRCA1; Breast cancer type 1 susceptibility protein; breast cancer type 1 susceptibility protein; OTTHUMP00000212143; OTTHUMP00000212147; OTTHUMP00000212148; OTTHUMP00000212149; OTTHUMP00000212150; OTTHUMP00000212151; OTTHUMP00000212155; RING finger protein 53; BRCA1/BRCA2-containing complex, subunit 1; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein; breast cancer 1, early onset; RING finger protein 53

BRCA1; BRCA1; IRIS; PSCP; BRCAI; BRCC1; PNCA4; RNF53; BROVCA1; RNF53

BRCA1_HUMAN

Monoclonal

IgG1 kappa

Mouse

1863

Anti-BRCA1 [Murine MAb recognizes full-length BRCA1, a 220 kDa nuclear phosphoprotein.]. This antibody recognizes full-length BRCA1, a 220 kD nuclear phosphoprotein. In a high proportion of breast and ovarian cancer cell lines, BRCA1 aberrantly mislocates to the cytoplasm. Its usefulness to monitor functional inactivation of BRCA1 in sporadic breast cancers is under active investigation.

100 ug Protein G purified antibody in PBS, pH 7.4

This antibody is stable for at least one (1) year at -70 degree C. Avoid multiple freeze thaw cycles.

Immunoblot, Immunoprecipitation

Immunoblotting: use at 1-10 ug/ml. Immunoprecipitation: use at 1-10 ug/ml. Positive controls: Any normal human tissue, especially those containing rapidly proliferating cells, such aslymphoid germinal centers.

Antigen: GST fusion protein expressedin E. coli corresponding to aa 341-748of full-length BRCA1.

Stabilizer: None. Preservatives: None. Available on request. Dilutions Instructions: Dilute in PBS or medium which is identical to that used in the assay system.

Cancer Research Products

Chen, Y et al. (1995) Science 270: 789-791; Chen, C-F et al. (1995) J Biol Chem 271: 32863-32868; Chen, Y et al. (1996) Cancer Res 56: 3168-3172.

1698399

AAC37594.1

P38398

207,721 Da

ATF-2 Transcription Factor Network Pathway 138006!!ATM Mediated Phosphorylation Of Repair Proteins Pathway 105865!!ATM Mediated Response To DNA Double-strand Break Pathway 105864!!Androgen Receptor Signaling Pathway 198806!!Aurora A Signaling Pathway 137925!!BARD1 Signaling Events Pathway 137959!!Coregulation Of Androgen Receptor Activity Pathway 138085!!DNA Repair Pathway 105837!!Double-Strand Break Repair Pathway 105861!!E2F Transcription Factor Network Pathway 137934

This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq]

Function: E3 ubiquitin-protein ligase that specifically mediates the formation of 'Lys-6'-linked polyubiquitin chains and plays a central role in DNA repair by facilitating cellular responses to DNA damage. It is unclear whether it also mediates the formation of other types of polyubiquitin chains. The E3 ubiquitin-protein ligase activity is required for its tumor suppressor function. The BRCA1-BARD1 heterodimer coordinates a diverse range of cellular pathways such as DNA damage repair, ubiquitination and transcriptional regulation to maintain genomic stability. Regulates centrosomal microtubule nucleation. Required for normal cell cycle progression from G2 to mitosis. Required for appropriate cell cycle arrests after ionizing irradiation in both the S-phase and the G2 phase of the cell cycle. Involved in transcriptional regulation of P21 in response to DNA damage. Required for FANCD2 targeting to sites of DNA damage. May function as a transcriptional regulator. Inhibits lipid synthesis by binding to inactive phosphorylated ACACA and preventing its dephosphorylation. Contributes to homologous recombination repair (HRR) via its direct interaction with PALB2, fine-tunes recombinational repair partly through its modulatory role in the PALB2-dependent loading of BRCA2-RAD51 repair machinery at DNA breaks. Ref.11 Ref.20 Ref.22 Ref.23 Ref.25 Ref.26 Ref.30 Ref.32 Ref.36 Ref.39 Ref.42 Ref.44. Enzyme regulation: The E3 ubiquitin-protein ligase activity is inhibited by phosphorylation by STK6/AURKA. Activity is increased by phosphatase treatment. Ref.32. Pathway: Protein modification; protein ubiquitination. Subunit structure: Heterodimer with BARD1. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Component of the BRCA1-A complex, at least composed of the BRCA1, BARD1, UIMC1/RAP80, FAM175A/Abraxas, BRCC3/BRCC36, BRE/BRCC45 and BABAM1/NBA1. Interacts (via BRCT domains) with FAM175A/Abraxas and RBBP8. Associates with RNA polymerase II holoenzyme. Interacts with SMC1A and COBRA1/NELFB. Interacts (via BRCT domains) with phosphorylated BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with DCLRE1C/Artemis and CLSPN. Interacts with H2AFX (phosphorylated on 'Ser-140'). Interacts with CHEK1/CHK1. Interacts with BRCC3. Interacts (via BRCT domains) with ACACA (phosphorylated); the interaction prevents dephosphorylation of ACACA. Interacts with STK6/AURKA. Interacts with UBXN1. Part of a trimeric complex containing BRCA1, BRCA2 and PALB2. Interacts with PALB2 and this interaction is essential for its function in HRR. Interacts with BRCA2 only in the presence of PALB2 which serves as the bridging protein. Ref.9 Ref.10 Ref.14 Ref.15 Ref.16 Ref.18 Ref.19 Ref.20 Ref.21 Ref.22 Ref.24 Ref.25 Ref.26 Ref.27 Ref.28 Ref.30 Ref.31 Ref.33 Ref.34 Ref.36 Ref.42 Ref.44 Ref.45 Ref.49 Ref.50 Ref.51. Subcellular location: Nucleus. Note: Localizes at sites of DNA damage at double-strand breaks (DSBs); recruitment to DNA damage sites is mediated by the BRCA1-A complex. Ref.3 Ref.8 Ref.9 Ref.36 Ref.49Isoform 3: Cytoplasm Ref.3 Ref.8 Ref.9 Ref.36 Ref.49. Isoform 5: Cytoplasm Ref.3 Ref.8 Ref.9 Ref.36 Ref.49. Tissue specificity: Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines. Ref.3. Domain: The BRCT domains recognize and bind phosphorylated pSXXF motif on proteins. The interaction with the phosphorylated pSXXF motif of FAM175A/Abraxas, recruits BRCA1 at DNA damage sites. Ref.53The RING-type zinc finger domain interacts with BAP1. Ref.53. Post-translational modification: Phosphorylation at Ser-308 by STK6/AURKA is required for normal cell cycle progression from G2 to mitosis. Phosphorylated in response to IR, UV, and various stimuli that cause checkpoint activation, probably by ATM or ATR. Ref.13 Ref.17 Ref.26 Ref.29 Ref.32 Ref.35 Ref.37 Ref.38 Ref.43Autoubiquitinated, undergoes 'Lys-6'-linked polyubiquitination. 'Lys-6'-linked polyubiquitination does not promote degradation. Polymorphism: There is evidence that the presence of the rare form of Gln-356-Arg and Leu-871-Pro polymorphisms may be associated with an increased risk for developing ovarian cancer. Involvement in disease: Defects in BRCA1 are a cause of susceptibility to breast cancer (BC) [. MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Note=Mutations in BRCA1 are thought to be responsible for 45% of inherited breast cancer. Moreover, BRCA1 carriers have a 4-fold increased risk of colon cancer, whereas male carriers face a 3-fold increased risk of prostate cancer. Cells lacking BRCA1 show defects in DNA repair by homologous recombination. Ref.1 Ref.14 Ref.47 Ref.49 Ref.52 Ref.55 Ref.56 Ref.57 Ref.58 Ref.60 Ref.61 Ref.62 Ref.63 Ref.64 Ref.66 Ref.70 Ref.71 Ref.74Defects in BRCA1 are a cause of susceptibility to breast-ovarian cancer familial type 1 (BROVCA1) [. MIM:604370]. A condition associated with familial predisposition to cancer of the breast and ovaries. Characteristic features in affected families are an early age of onset of breast cancer (often before age 50), increased chance of bilateral cancers (cancer that develop in both breasts, or both ovaries, independently), frequent occurrence of breast cancer among men, increased incidence of tumors of other specific organs, such as the prostate. Note=Mutations in BRCA1 are thought to be responsible for more than 80% of inherited breast-ovarian cancer. Ref.59 Ref.60 Ref.71 Ref.74Note=Defects in BRCA1 are associated with genetic susceptibility to ovarian cancer. Sequence similarities: Contains 2 BRCT domains.Contains 1 RING-type zinc finger.

0.1 mg

420 USD